Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.39 |
| ▸ | BRS3 | P32247 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933049 | 0.86 | KDM4C (0.46) | NAMPTCYP17A1RXFP1METAP1ATR | |
| SCHEMBL12190376 | 0.86 | NAMPT (0.49) | NAMPTCYP17A1RXFP1METAP1ATR | |
| SCHEMBL5551442 | 0.84 | SIRT3 (0.47) | NAMPTCYP17A1RXFP1METAP1ATR | |
| SCHEMBL950258 | 0.84 | ATR (0.53) | NAMPTCYP17A1ATRRAB9AIDO1 | |
| SCHEMBL28764741 | 0.83 | NAMPT (0.44) | NAMPTCYP17A1RXFP1METAP1ATR | |
| SCHEMBL18522430 | 0.82 | NAMPT (0.50) | NAMPTCYP17A1METAP1ATRRAB9A | |
| SCHEMBL2107971 | 0.80 | NAMPT (0.48) | NAMPTCYP17A1METAP1ATRRAB9A | |
| SCHEMBL3666785 | 0.80 | NAMPT (0.48) | NAMPTCYP17A1METAP1ATRRAB9A | |
| SCHEMBL15919261 | 0.79 | NAMPT (0.41) | NAMPTCYP17A1RXFP1METAP1ATR | |
| SCHEMBL16676647 | 0.78 | KDM4C (0.58) | NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | disclosed |
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | disclosed |
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | disclosed |
| EP-1869037-B1 | HETEROBICYLIC INHIBITORS OF HVC | TIBOTEC PHARM LTD (IE) | 2011-07-27 | — | — | EP | disclosed |
| EP-1869037-B1 | HETEROBICYLIC INHIBITORS OF HVC | TIBOTEC PHARM LTD (IE) | 2011-07-27 | — | — | EP | disclosed |
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | TIBOTEC BVBA (BE) | 2008-07-31 | — | — | US | disclosed |
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | TIBOTEC BVBA (BE) | 2008-07-31 | — | — | US | disclosed |
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | TIBOTEC BVBA (BE) | 2008-07-31 | — | — | US | disclosed |
| EP-1869037-A1 | HETEROBICYLIC INHIBITORS OF HVC | Tibotec Pharmaceuticals Ltd. (IE) | 2007-12-26 | — | — | EP | disclosed |
| US-20070066632-A1 | Fused bicyclic inhibitors of TGFbeta | SCIOS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066632-A1 | Fused bicyclic inhibitors of TGFbeta | SCIOS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066632-A1 | Fused bicyclic inhibitors of TGFbeta | SCIOS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2006100310-A1 | HETEROBICYLIC INHIBITORS OF HCV | TIBOTEC PHARMACEUTICALS LTD (IE) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | HAVCR2, GTF3C4, CUL4A | NAMPT 265/4885NUDT1 26/4885CYP17A1 4363/4885 |
| US-20070066632-A1 | Fused bicyclic inhibitors of TGFbeta | TGFBR1, TGFB1, SMAD2 | NAMPT 1376/4885NUDT1 217/4885CYP17A1 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.